To review the pharmacology, efficacy, safety, and tolerability of RotaTeq and RotaRix, 2 rotavirus vaccines.
Data Sources:
English-language articles were obtained via MEDLINE (1966-August 2009) and EMBASE (1980-August 2009) searches using the key words rotavirus vaccine, epidemiology, diarrhea, intussusception, RotaShield, RotaTeq, and RotaRix. Bibliographies of selected articles were used to identify additional sources.
Study Selection and Data Extraction:
Available published articles reporting the results of human studies of rotavirus vaccines were reviewed for inclusion in this article. Additional information regarding clinical trials and adverse events was obtained from the manufacturer's prescribing information for each vaccine.
Data Synthesis:
RotaTeq is a live, attenuated human-bovine pentavalent vaccine, and RotaRix is a live, attenuated human vaccine. Both vaccines are approved for the prevention of rotavirus infection and recommended for routine immunization in healthy infants aged 14 weeks to 8 months. The vaccines differ in virologic characteristics, but clinical trials indicate similar efficacy and safety. Each vaccine is more than 70% effective in preventing any severity of rotavirus gastroenteritis and more than 98% effective in preventing severe disease through one full season of rotavirus exposure postvaccination. Efficacy begins to wane during the second season of rotavirus exposure. Post hoc analyses of clinical trials indicated an 85–100% reduction in hospitalizations and emergency department visits following vaccination. Both vaccines have been well tolerated. Fever, vomiting, and diarrhea are the most reported adverse events. Intussusception and Kawasaki syndrome have been reported, but occurrence of these events has not been shown to be significant in comparison with the background rate for each adverse event.
Conclusions:
RotaTeq and RotaRix are effective for the prevention of rotavirus infection in the US, Europe, and Latin America. Additional studies are needed to assess their duration of protection, worldwide efficacy, effect on the reduction of healthcare resource utilization, and adverse event monitoring.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. Rotavirus vaccines: WHO position paper. Wkly Epidemiol Rec2007; 82: 285–96.
2.
ParasharUDHummelmanEGBreseeJSMillerMAGlassRI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis2003; 9: 565–72.
3.
ButzAMFosarelliPDickJCusackTYolkenR. Prevalence of rotavirus on high-risk fomites in day-care facilities. Pediatrics1993; 92: 202–5.
4.
Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children. MMWR Recomm Rep2006; 55: 1–13.
5.
TurciosRMCurnsATHolmanRC. Temporal and geographic trends of rotavirus activity in the United States 1997–2004. Pediatr Infect Dis J2006; 25: 451–4. DOI 10.1097/01.inf.0000214987.67522.78
6.
FischerTKViboudCParasharU. Hospitalizations and deaths from diarrhea and rotavirus among children less than 5 years of age in the United States, 1993–2003. J Infect Dis2007; 195: 1117–25. DOI 10.1086/512863
Product information. RotaRix (human live attenuated rotavirus vaccine). Research Triangle Park, NC: GlaxoSmithKline, April 2008.
9.
HoshinoYKapikianAZ. Rotavirus serotypes: Classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr2000; 18 (Jun): 5–14.
10.
GirardMPSteeleDChaignatCLKienyMP. A review of vaccine research and development: Human enteric infections. Vaccine2006; 24: 2732–50. DOI 10.1016/j.vaccine.2005.10.014
SantosNHoshinoY. Global distribution of rotavirus sero types/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol2005; 15: 29–56. DOI 10.1002/rmv.448
13.
Centers for Disease Control and Prevention. Rotavirus surveillance—worldwide, 2001–2008. MMWR Morb Mortal Wkly Rep2008; 57: 1255–7.
14.
SteeleADIvanoffB. Rotavirus strains circulating in Africa during 1996–1999: Emergence of G9 strains and P[6] strains. Vaccine2003; 21: 361–7. DOI 10.1016/s0264–410x(02)00616–3
15.
CunliffeNAKilgorePEBreseeJS. Epidemiology of rotavirus diarrhea in Africa: A review to assess the need for rotavirus immunization. Bull World Health Organ1998; 76: 525–37.
16.
CastelloAAArvayMLGlassRIGentschJ. Rotavirus strain surveillance in Latin America: A review of the last nine years. Pediatr Infect Dis J2004; 23: S168–72. DOI 10.1097/01.inf.0000142466.57262.2a
17.
SmithMJClarkHFLawleyD. The clinical and molecular epidemiology of community- and healthcare-acquired rotavirus gastroenteritis. Pediatr Infect Dis J2008; 27: 54–8. DOI 10.1097/INF.0b013e31814b279d
18.
RamanchandranMGentschJRParasharUD. Detection and characterization of novel rotavirus strains in the United States. J Clin Microbiol1998; 36: 3223–9.
19.
GriffinDDKirkwoodCDParasharUD. Surveillance of rotavirus strains in the United States: Identification of unusual strains. J Clin Microbiol2000; 38: 2784–7.
20.
WardRL. Rotavirus vaccines: How they work or don't work. Expert Rev Mol Med2008; 10: 1–10. DOI 10.1017/S1462399408000574
VelazquezFRMatsonDOCalvaJJ. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med1996; 335: 1022–8. DOI 10.1056/NEJM199610033351404
23.
Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children—recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep1999; 48: 1–23.
24.
RennelsMBGlassRIDennehyPH. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines—report of the national multicenter trial (United States Rotavirus Vaccine Efficacy Group). Pediatrics1996; 97: 7–13.
25.
SantoshamMMoultonLHReidR. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr1997; 131: 632–8.
26.
Perez-SchaelIGuntinasMJPerezM. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med1997; 337: 1181–7. DOI 10.1056/NEJM199710233371701
27.
JoensuuJKoskenniemiEPangX-LVesikariT. Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet1997; 350: 1205–9. DOI 10.1016/S0140–6736(97)05118–0
28.
Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep1999; 48: 1007.
Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine—United States, 1998–1999. MMWR Morb Mortal Wkly Rep1999; 48: 577–81.
32.
MurphyTVGargiulloPMMassoudiMS. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med2001; 344: 564–72. DOI 10.1056/NEJM200102223440804
33.
Product information. RotaShield (rhesus-human reassortant tetravalent rotavirus vaccine). Philadelphia, PA: Wyeth-Lederle Vaccines and Pediatrics, August 1998.
34.
SimonsenLViboudCElixhauserATaylorRJKapikianAZ. More on RotaShield and intussusceptions: The role of age at time of vaccination. J Infect Dis2005; 192: S36–43. DOI 10.1086/431512
35.
PeterGMyersMG. Intussusception, rotavirus, and oral vaccines: Summary of a workshop. Pediatrics2002; 110: e67.
36.
RothmanKJYoung-XuYArellanoF. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception (letter). J Infect Dis2006; 193: 898. DOI 10.1086/500217
37.
World Health Organization. Report of the Global Advisory Committee on Vaccine Safety, December 1–2, 2005. Wkly Epidemiol Rec2006; 2: 16–7.
38.
VesikariTMatsonDODennehyP. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med2006; 354: 23–33. DOI 10.1056/NEJMoa052664
39.
RodriguezZMGoveiaMGStekJE. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J2007; 26: 221–7. DOI 10.1097/01.inf.0000254391.71103.e8
40.
GoveiaMGRodriguezZMDallasMJ. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J2007; 26: 1099–104. DOI 10.1097/INF.0b013e31814521cb
41.
BlockSLVesikariTGoveiaMG. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf-life. Pediatrics2007; 119: 11–8.
42.
Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity—United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep2008; 57: 697–700.
43.
AndersonEJ. Rotavirus vaccines: Viral shedding and risk of transmission. Lancet Infect Dis2008; 8: 642–9. DOI 10.1016/S1473–3099(08)70231–7
44.
DennehyPHGoveiaMGDallaMJHeatonPM. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis2007; 11: S36–42. DOI 10.1016/S1201–9712(07)60020–4
45.
MatsonDO. The pentavalent rotavirus vaccine, RotaTeq. Semin Pediatr Infect Dis2006; 17: 195–9. DOI 10.1053/j.spid.2006.08.005
46.
Centers for Disease Control and Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination—United States, February 1, 2006-February 15, 2007. MMWR Morb Mortal Wkly Rep2007; 56: 218–22.
47.
HaberPPatelMIzurietaHS. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006 to September 25, 2007. Pediatrics2008; 121: 1206–12.
48.
Centers for Disease Control and Prevention. Kawasaki syndrome: history and definition. www.cdc.gov/kawasaki (accessed 2009 Aug 5).
49.
MatsunoSUtagawaE. Association of rotavirus infection with Kawasaki syndrome (letter). J Infect Dis1983; 148: 177.
50.
YeungRSM. Pathogenesis and treatment of Kawasaki's disease. Curr Opin Rheumatol2005; 17: 617–23. DOI 10.1097/01.bor.0000174184.15901.ee
51.
GeierDAKingPGSykesSKGeierMR. RotaTeq vaccine adverse events and policy considerations. Med Sci Monit2008; 14:PH9–16.
52.
World Health Organization. Report of the Global Advisory Committee on Vaccine Safety, December 12–13, 2007. Wkly Epidemiol Rec2008; 83: 37–44.
53.
Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children—recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep2009; 58: 1–25.
54.
Ruiz-PalaciosGMPerez-SchaelIVelazquezFR. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med2006; 354: 11–22. DOI 10.1056/NEJMoa052434
55.
LinharesACVelazquezFRPerez-SchaelI. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: A randomized, double-blind, placebo-controlled phase III study. Lancet2008; 371: 1181–9. DOI 10.1016/S0140–6736(08)60524–3
56.
VesikariTKarvonenAPrymulaR. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: Randomized, double-blind controlled study. Lancet2007; 370: 1757–63. DOI 10.1016/S0140–3736(07)61744–9
57.
SalinasBSchaelPerez ILinharesAC. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. Pediatr Infect Dis J2005; 24: 807–16. DOI 10.1097/01.inf.0000178294.13954.a1
58.
PhuaKBQuakSHLeeBW. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis2005; 192: S6–16. DOI 10.1086/431511
59.
DennehyPHBradyRCHalperinSA. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J2005; 24: 481–8. DOI 10.1097/01.inf.0000164763.55558.71
VesikariTKarvonenAPuustinenL. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J2004; 23: 937–43. DOI 10.1097/01.inf.0000141722.10130.50
62.
ShahSIRayjadaN. Rationale and implementation policy for use of oral, live, reassortant rotavirus vaccine in the neonatal intensive care unit. Adv Neonatal Care2008; 8: 148–9.
63.
ChandranAHeinzenRRSantoshamMSiberryGK. Nosocomial rotavirus infections: A systematic review. J Pediatr2006; 149: 441–7. DOI 10.1016/j.jpeds.2006.04.054
64.
Van der WielenMVan DammeP. Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: A review of the data from the rotavirus efficacy and safety trial. Eur J Clin Microbiol Infect Dis2008; 27: 495–501. DOI 10.1007/s100096-008-0479-5
DaskalakiISpainCVLongSSWatsonB. Implementation of rotavirus immunization in Philadelphia, Pennsylvania: High levels of vaccine ineligibility and off-label use. Pediatrics2008; 122: e33–8. DOI 10.1542/peds.2007–2464
69.
VesikariTItzlerRMatsonDO. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis2007; 11: S29–35. DOI 10.1016/S1201–9712(07)60019–8
70.
Givon-LaviNGreenbergDDaganR. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine2008; 46: 5798–801.
